Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
13 Settembre 2024 - 10:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ |
Preliminary Proxy Statement
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive Proxy Statement
|
| ☒ |
Definitive Additional Materials
|
|
☐
|
Soliciting Material Pursuant to §240.14a-12
|
|
Moleculin Biotech, Inc.
|
|
(Name of Registrant as Specified in its Charter)
|
| |
| |
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
Payment of Filing Fee (Check the appropriate box):
|
☐
|
Fee paid previously with preliminary materials.
|
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
Grafico Azioni Moleculin Biotech (NASDAQ:MBRX)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Moleculin Biotech (NASDAQ:MBRX)
Storico
Da Gen 2024 a Gen 2025
